<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">endofocus</journal-id><journal-title-group><journal-title xml:lang="ru">FOCUS Эндокринология</journal-title><trans-title-group xml:lang="en"><trans-title>FOCUS. Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-0177</issn><issn pub-type="epub">2713-0185</issn><publisher><publisher-name>ООО "Издательство "Перо"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.62751/2713-0177-2026-7-2-11</article-id><article-id custom-type="elpub" pub-id-type="custom">endofocus-227</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group></article-categories><title-group><article-title>Кардио-рено-метаболический синдром: мультиморбидный пациент и стратегия кардио- и нефропротекции</article-title><trans-title-group xml:lang="en"><trans-title>Cardiorenal metabolic syndrome: A clinical case of a multimorbid patient and rationale for cardio- and nephroprotective therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1385-0245</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Измайлова</surname><given-names>М. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Izmailova</surname><given-names>M. Ya.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Измайлова Марьям Ярагиевна – ассистент кафедры эндокринологии ИКМ </p><p>Москва </p></bio><bio xml:lang="en"><p>Maryam Ya. Izmailova – assistant at the Department of endocrinology </p><p>Moscow </p></bio><email xlink:type="simple">maremizm@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3911-8543</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аракелов</surname><given-names>С. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Arakelov</surname><given-names>S. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аракелов Сергей Эрнестович – д. м. н., профессор, главный врач</p><p>Москва </p></bio><bio xml:lang="en"><p>Sergey E. Arakelov – Dr. Sci. (Med.), professor, chief physician </p><p>Moscow </p></bio><email xlink:type="simple">doctorgkv@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7675-4496</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баирова</surname><given-names>В. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Bairova</surname><given-names>V. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Баирова Валерия Эдуардовна – ассистент кафедры эндокринологии ИКМ </p><p>117997, г. Москва, ул. Островитянова, д. 1.  </p></bio><bio xml:lang="en"><p>Valeriia E. Bairova – assistant at the Department of endocrinology, Institute of Clinical Medicine </p><p>1 Ostrovityanova St., Moscow, 117997 </p></bio><email xlink:type="simple">bairova.lera@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-3623-8445</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бусел</surname><given-names>К. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Busel</surname><given-names>K. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бусел Камила Рустамовна – клинический ординатор </p><p>Москва </p></bio><bio xml:lang="en"><p>Kamila R. Busel – clinical resident </p><p>Moscow </p></bio><email xlink:type="simple">kamimilka994@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Городская клиническая больница имени В.П. Демихова ДЗМ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.P. Demikhov City Clinical Hospital of the Moscow City Department of Health</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>11</day><month>07</month><year>2026</year></pub-date><volume>7</volume><issue>2</issue><fpage>79</fpage><lpage>84</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Измайлова М.Я., Аракелов С.Э., Баирова В.Э., Бусел К.Р., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Измайлова М.Я., Аракелов С.Э., Баирова В.Э., Бусел К.Р.</copyright-holder><copyright-holder xml:lang="en">Izmailova M.Y., Arakelov S.E., Bairova V.E., Busel K.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://endofocus.elpub.ru/jour/article/view/227">https://endofocus.elpub.ru/jour/article/view/227</self-uri><abstract><p>В статье представлен клинический случай пациента с впервые выявленным сахарным диабетом 2 типа (СД2), у которого выраженная декомпенсация углеводного обмена, вероятно, способствовала ухудшению течения хронической сердечной недостаточности со сниженной фракцией выброса на фоне хронической болезни почек смешанного генеза. Особое внимание уделено стратегии выбора кардио- и ренопротективной терапии с применением препаратов из группы ингибиторов натрий-глюкозного котранспортера 2 типа, ингибиторов ангиотензинпревращающего фермента и высокоселективных антагонистов минералокортикоидных рецепторов с целью своевременного многофакторного терапевтического воздействия на разные компоненты кардио-рено-метаболического синдрома у мультиморбидного пациента. В представленном клиническом случае длительное бессимптомное течение СД2 (уровень гликированного гемоглобина – 17,5%) на фоне кардио-рено-метаболического синдрома могло послужить триггером развития нарушения ритма, потребовавшего проведения электроимпульсной терапии. Описанные данные демонстрируют необходимость активного скрининга углеводного обмена у пациентов высокого и очень высокого риска сердечно-сосудистых осложнений, а также важность междисциплинарного подхода к ведению таких больных. </p></abstract><trans-abstract xml:lang="en"><p>The paper presents a clinical case of a patient with newly diagnosed type 2 diabetes mellitus (T2 DM), in whom severe decompensation of carbohydrate metabolism probably contributed to the worsening of chronic heart failure with a reduced ejection fraction against the background of chronic kidney disease of mixed genesis. Special attention is paid to the strategy of choosing cardio- and renoprotective therapy using drugs from the group of sodium-glucose cotransporter type 2 inhibitors, angiotensin converting enzyme inhibitors and highly selective antagonists of mineralocorticoid receptors in order to timely multifactorial therapeutic effects on various components of cardioreno-metabolic syndrome in a multimorbid patient. In the presented clinical case, a long-term asymptomatic course of T2DM2 (glycated hemoglobin level – 17.5%), against the background of cardio-reno-metabolic syndrome, could serve as a trigger in the development of rhythm disturbances that required electro-pulse therapy. The clinical case demonstrates the need for active screening of carbohydrate metabolism in patients at high and very high risk of cardiovascular complications, as well as the importance of an interdisciplinary approach in the management of such patients. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 2 типа</kwd><kwd>хроническая сердечная недостаточность</kwd><kwd>хроническая болезнь почек</kwd><kwd>кардио-рено-метаболический континуум</kwd><kwd>ингибиторов натрий-глюкозного котранспортера 2 типа</kwd><kwd>эмпаглифлозин</kwd><kwd>финеренон</kwd><kwd>фибрилляция предсердий</kwd><kwd>полиморбидность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>type 2 diabetes mellitus</kwd><kwd>chronic heart failure</kwd><kwd>chronic kidney disease</kwd><kwd>cardiorenal metabolic continuum</kwd><kwd>sodium-glucose cotransporter 2 inhibitors</kwd><kwd>empagliflozin</kwd><kwd>finerenone</kwd><kwd>atrial fibrillation</kwd><kwd>polymorbidity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Supplement_1):S207-S238. doi:10.2337/dc25-S010</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Supplement_1):S207-S238. doi:10.2337/dc25-S010</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Schnetzer L., Leiherer A., Festa A., et al. Type 2 diabetes and chronic kidney disease as long-term predictors of cardiovascular events in patients with coronary artery disease. European Journal of Clinical Investigation. 2024;54(12):e14374. doi:10.1111/eci.14374</mixed-citation><mixed-citation xml:lang="en">Schnetzer L., Leiherer A., Festa A., et al. Type 2 diabetes and chronic kidney disease as long-term predictors of cardiovascular events in patients with coronary artery disease. European Journal of Clinical Investigation. 2024;54(12):e14374. doi:10.1111/eci.14374</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ndumele C.E., Rangaswami J., Chow S.L., et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-1635. doi:10.1161/CIR.0000000000001184</mixed-citation><mixed-citation xml:lang="en">Ndumele C.E., Rangaswami J., Chow S.L., et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-1635. doi:10.1161/CIR.0000000000001184</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Turagam M.K., Velagapudi P., Kocheril A.G. The cardiorenal metabolic syndrome: a new paradigm in cardiovascular medicine. Journal of the American College of Cardiology. 2023;81(15):1489-1502. doi:10.1016/j.jacc.2023.02.042</mixed-citation><mixed-citation xml:lang="en">Turagam M.K., Velagapudi P., Kocheril A.G. The cardiorenal metabolic syndrome: a new paradigm in cardiovascular medicine. Journal of the American College of Cardiology. 2023;81(15):1489-1502. doi:10.1016/j.jacc.2023.02.042</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720</mixed-citation><mixed-citation xml:lang="en">Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389</mixed-citation><mixed-citation xml:lang="en">Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Marso S.P., Bain S.C., Consoli A., et al. SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal ofMedicine. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141</mixed-citation><mixed-citation xml:lang="en">Marso S.P., Bain S.C., Consoli A., et al. SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal ofMedicine. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bakris G.L., Agarwal R., Anker S.D., et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845</mixed-citation><mixed-citation xml:lang="en">Bakris G.L., Agarwal R., Anker S.D., et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Solomon S.D., McMurray J.J.V., Vaduganathan M., et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. New England Journal ofMedicine. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107</mixed-citation><mixed-citation xml:lang="en">Solomon S.D., McMurray J.J.V., Vaduganathan M., et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. New England Journal ofMedicine. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Heerspink H.J.L., Vart P., Jongs N., et al. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials. Diabetes, Obesityand Metabolism. 2023;25(11):3327-3336. doi:10.1111/dom.15232</mixed-citation><mixed-citation xml:lang="en">Heerspink H.J.L., Vart P., Jongs N., et al. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials. Diabetes, Obesityand Metabolism. 2023;25(11):3327-3336. doi:10.1111/dom.15232</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Carlisle M.A., Fudim M., DeVore A.D., et al. Heart Failure and Atrial Fibrillation: Like Love and Marriage or Friends With Benefits? Journal of the American College of Cardiology. 2019;74(18):2231-2233. doi:10.1016/j.jacc.2019.08.1032</mixed-citation><mixed-citation xml:lang="en">Carlisle M.A., Fudim M., DeVore A.D., et al. Heart Failure and Atrial Fibrillation: Like Love and Marriage or Friends With Benefits? Journal of the American College of Cardiology. 2019;74(18):2231-2233. doi:10.1016/j.jacc.2019.08.1032</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Seferović P.M., Paulus W.J., Rosano G., et al. Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial &amp; Pericardial Diseases. European Journal of Heart Failure. 2024;26(9):1893-1903. doi:10.1002/ejhf.3347</mixed-citation><mixed-citation xml:lang="en">Seferović P.M., Paulus W.J., Rosano G., et al. Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial &amp; Pericardial Diseases. European Journal of Heart Failure. 2024;26(9):1893-1903. doi:10.1002/ejhf.3347</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. doi:10.1016/S0140-6736(20)31824-9</mixed-citation><mixed-citation xml:lang="en">Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. doi:10.1016/S0140-6736(20)31824-9</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">McGuire D.K., Shih W.J., Cosentino F., et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiology. 2021;6(2):148-158. doi:10.1001/jamacardio.2020.4511</mixed-citation><mixed-citation xml:lang="en">McGuire D.K., Shih W.J., Cosentino F., et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiology. 2021;6(2):148-158. doi:10.1001/jamacardio.2020.4511</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Pitt B., Filippatos G., Agarwal R., et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956</mixed-citation><mixed-citation xml:lang="en">Pitt B., Filippatos G., Agarwal R., et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Filippatos G., Anker S.D., Agarwal R., et al. Finerenonereduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983</mixed-citation><mixed-citation xml:lang="en">Filippatos G., Anker S.D., Agarwal R., et al. Finerenonereduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Rossing P., Agarwal R., Green J.B., et al. Finerenone and empagliflozin in patients with type 2 diabetes and chronic kidney disease according to baseline GLP-1 receptor agonist use: a prespecified analysis of the CONFIDENCE trial. Diabetes Care. 2025;48(11):1904-1913. doi:10.2337/dc25-1673</mixed-citation><mixed-citation xml:lang="en">Rossing P., Agarwal R., Green J.B., et al. Finerenone and empagliflozin in patients with type 2 diabetes and chronic kidney disease according to baseline GLP-1 receptor agonist use: a prespecified analysis of the CONFIDENCE trial. Diabetes Care. 2025;48(11):1904-1913. doi:10.2337/dc25-1673</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mortada I., Lee A.W., Sahu A., et al. Additive Cardiorenal Benefits of Finerenone and SGLT2 Inhibitor Combination Therapy in Diabetic CKD: A Propensity-Matched Real-World Study. American Journal of Cardiology. 2026; published online February 28. doi:10.1016/j.amjcard.2026.02.035</mixed-citation><mixed-citation xml:lang="en">Mortada I., Lee A.W., Sahu A., et al. Additive Cardiorenal Benefits of Finerenone and SGLT2 Inhibitor Combination Therapy in Diabetic CKD: A Propensity-Matched Real-World Study. American Journal of Cardiology. 2026; published online February 28. doi:10.1016/j.amjcard.2026.02.035</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
